Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin
NCT00395421 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114
Last updated 2010-06-10
Summary
This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.
Conditions
- Chronic Hepatitis C
Interventions
- DRUG
-
NM283 plus Peg-IFNα-2a
200 mg QD 180 µg QW
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-10-31
- Primary Completion
- 2008-06-30
- Completion
- 2008-08-31
Countries
- United States
Study Locations
More Related Trials
-
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
NCT01281839 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
NCT00495391 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients
NCT01797848 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment
NCT00980330 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
NCT00637923 ·Status: COMPLETED ·Phase: PHASE2
-
TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy
NCT01485991 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
NCT01725529 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
NCT01846832 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
NCT00851890 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
NCT01724086 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection
NCT01273948 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C
NCT00418054 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)
NCT00895882 ·Status: WITHDRAWN ·Phase: PHASE2
-
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants
NCT01290679 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
NCT02593162 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)
NCT01358864 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
NCT01125189 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
NCT01121705 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
NCT01795911 ·Status: COMPLETED ·Phase: PHASE2
-
4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
NCT00905632 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C
NCT01903954 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
NCT00854802 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)
NCT01343888 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
NCT01309932 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
NCT01165359 ·Status: COMPLETED ·Phase: PHASE1